Skip to main
IMTX

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV presents a positive outlook largely due to the promising performance of its anzu-cel asset, particularly in the ongoing Phase 3 SUPRAME study, which aims to demonstrate a meaningful increase in progression-free survival (PFS) over control. The company's innovative ACTengine platform enhances manufacturing logistics, achieving a notable 98% success rate and a swift 14-day turnaround for product release, thereby positioning it competitively within the market. Additionally, the recent RMAT designation from the FDA for anzu-cel underscores its potential in addressing high unmet medical needs within the lucrative market of metastatic cancers, emphasizing the strategic growth opportunities for Immatics in the near future.

Bears say

The financial outlook for Immatics NV is negative due to underwhelming clinical data presented for their lead candidate, Brenetafusp, which achieved only an 11% overall response rate and a 56% disease control rate in a key patient segment, raising concerns about its commercial viability. Additionally, the company faces multifaceted risks, including potential setbacks in research and development, regulatory challenges, and competitive pressures that could further hinder product sales and financial projections. Finally, anticipated downward revisions to risk-adjusted projections cast uncertainty over the company's valuation, with a downside scenario suggesting a valuation as low as $3 per share if key milestones are not met.

Immatics NV (IMTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.